Clavic-Q-RE is a cutting-edge immunotherapy and cancer treatment pioneered by RGCC. This therapy harnesses the power of the immune system to target and combat cancer cells effectively.
Requires 150ml of blood in 5-6 blood sample vials (25-30ml in each)
It is suitable for cancer patients with solid tumors, and hematological malignancies, independent of the stage.
Immune-Frame and Oncotrace tests should be ordered along with Clavic-Q-Re, to check the immune system and set a baseline respectively. These tests are not included in the price of Clavic-Q-Re. To determine whether a patient is eligible for Clavic-Q-Re is based on Immune-Frame results.